<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370030</url>
  </required_header>
  <id_info>
    <org_study_id>R-2014-785-082</org_study_id>
    <nct_id>NCT02370030</nct_id>
  </id_info>
  <brief_title>Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.</brief_title>
  <acronym>CITRUSEP</acronym>
  <official_title>Controlled Randomized Multi-centric Clinical Trial on the Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple blind placebo-controlled study to determine if administering citrulline in patients
      with sepsis and severe sepsis slows progression to multiple organ failure and death,
      measuring biomarkers of endothelial dysfunction. Patients are divided into placebo or
      citrulline and followed up for 1 month.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients with sepsis are being recited from intensive care unite of IMSS at the
      CMN Siglo XXI and CMN La Raza over the period of november 2015 through june 2016. After
      signing an informed consent they will be randomized into 80 for intervention arm and 80 for
      the placebo arm. All patients will receive usual medical treatment; and during seven days
      citurlline arm subjects will receive supplementation with oral or nasogastric citrulline (10
      g/day), while other group patients will receive during seven days oral or nasogastric placebo
      (10 g/day) with no visible difference between these. Microalbuminuria and interleukines 1, 6,
      and 10 will be measured at randomization and at day 7. All subjects will be followed for 28
      days, and after the follow-up period results will be analyzed to determine de efficacy and
      safety of citrulline, primary outcome are the incidence of multiple organic failure and
      death, also microalbuminuria levels 1,6,10-interleukines. We will use Student-t and Chi2 for
      statistical analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple organ failure</measure>
    <time_frame>1 month</time_frame>
    <description>Progression to multiple organ failure ending in death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrulline malate</intervention_name>
    <description>Active comparator: 10 g/day citrulline malate during 7 days</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Citrulline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sepsis

          -  Severe sepsis

          -  Diagnosis of sepsis in the first 36 hours of hospitalization.

          -  Informed Consent

          -  Intestinal tract intact

        Exclusion Criteria:

          -  Terminal cancer

          -  Acute and chronic liver diseases

          -  Chronic renal failure.

          -  Acute renal failure AKIN III.

          -  Pregnant and postpartum women

          -  Dying patients.

          -  Patients with cardiac arrest.

          -  Active gastrointestinal bleeding.

          -  Steroids or immunosuppressants.

          -  Enrolled in another study intervention.

          -  Citrulline allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Almeida Gutierrez, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Coordinación de Investigación en Salud, México.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Almeida Gutierrez, MSc</last_name>
    <phone>+52-55-5627-6900</phone>
    <phone_ext>21230</phone_ext>
    <email>almeida_90210@yahoo.com.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>CME Centro Mèdico Siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonor Serrano, MS</last_name>
      <phone>+52-55-5627-6900</phone>
      <phone_ext>21445</phone_ext>
      <email>leotigger40@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CME La Raza</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Kao CC, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline and nitric oxide metabolism in sepsis. Clin Sci (Lond). 2009 Jun 2;117(1):23-30. doi: 10.1042/CS20080444.</citation>
    <PMID>19105791</PMID>
  </results_reference>
  <results_reference>
    <citation>Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HA, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh-McHugh A, Summar ML. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26.</citation>
    <PMID>17662768</PMID>
  </results_reference>
  <results_reference>
    <citation>Piton G, Manzon C, Monnet E, Cypriani B, Barbot O, Navellou JC, Carbonnel F, Capellier G. Plasma citrulline kinetics and prognostic value in critically ill patients. Intensive Care Med. 2010 Apr;36(4):702-6. doi: 10.1007/s00134-010-1751-6.</citation>
    <PMID>20084502</PMID>
  </results_reference>
  <results_reference>
    <citation>Piton G, Belon F, Cypriani B, Regnard J, Puyraveau M, Manzon C, Navellou JC, Capellier G. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. Crit Care Med. 2013 Sep;41(9):2169-76. doi: 10.1097/CCM.0b013e31828c26b5.</citation>
    <PMID>23782971</PMID>
  </results_reference>
  <results_reference>
    <citation>Luiking YC, Poeze M, Ramsay G, Deutz NE. Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production. Am J Clin Nutr. 2009 Jan;89(1):142-52. doi: 10.3945/ajcn.2007.25765. Epub 2008 Dec 3.</citation>
    <PMID>19056593</PMID>
  </results_reference>
  <results_reference>
    <citation>Kao C, Hsu J, Bandi V, Jahoor F. Alterations in glutamine metabolism and its conversion to citrulline in sepsis. Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1359-64. doi: 10.1152/ajpendo.00628.2012. Epub 2013 Apr 23.</citation>
    <PMID>23612995</PMID>
  </results_reference>
  <results_reference>
    <citation>Wijnands KA, Vink H, Briedé JJ, van Faassen EE, Lamers WH, Buurman WA, Poeze M. Citrulline a more suitable substrate than arginine to restore NO production and the microcirculation during endotoxemia. PLoS One. 2012;7(5):e37439. doi: 10.1371/journal.pone.0037439. Epub 2012 May 29.</citation>
    <PMID>22666356</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care. 2013 Jan 17;17(1):R10. doi: 10.1186/cc11934.</citation>
    <PMID>23327349</PMID>
  </results_reference>
  <results_reference>
    <citation>Cynober L. Citrulline: just a biomarker or a conditionally essential amino acid and a pharmaconutrient in critically ill patients? Crit Care. 2013 Mar 11;17(2):122. doi: 10.1186/cc12534.</citation>
    <PMID>23509945</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Eduardo Almeida Gutiérrez</investigator_full_name>
    <investigator_title>Head Researcher</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>citrulline</keyword>
  <keyword>endothelial</keyword>
  <keyword>toxemia</keyword>
  <keyword>endothelial determination of progression</keyword>
  <keyword>with vs without citrulline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

